Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual disorders Cover

.blurhash-client-img { display: none !important; }

Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual disorders

Endocrine Regulations

Volume 56 (2022): Issue 2 (April 2022)

By: Muhammad Ashfaq, Muhammad Zeeshan Haroon and Yasser MSA Alkahraman

Open Access

|Apr 2022

Authors

Muhammad Ashfaq

Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan

Muhammad Zeeshan Haroon

Department of Community Medicine, Ayub Medical College, Abbottabad, Pakistan

Yasser MSA Alkahraman

yasser@cuiatd.edu.pk

Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan

DOI: https://doi.org/10.2478/enr-2022-0015 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668

Journal RSS Feed

Language: English

Page range: 134 - 147

Published on: Apr 30, 2022

Published by: Slovak Academy of Sciences, Mathematical Institute

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

proton pump inhibitors,

hyperprolactinemia,

reproductive symptoms,

sexual dys-function,

erectile dysfunction

Related subjects:

Molecular biology,

Basic medical science,

Basic medical science, other,

Clinical medicine,

Internal medicine,

Endocrinology, diabetology

© 2022 Muhammad Ashfaq, Muhammad Zeeshan Haroon, Yasser MSA Alkahraman, published by Slovak Academy of Sciences, Mathematical Institute
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 56 (2022): Issue 2 (April 2022)Next article